<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pediatric Hematology/Oncology and Immunopathology</journal-id><journal-title-group><journal-title xml:lang="en">Pediatric Hematology/Oncology and Immunopathology</journal-title><trans-title-group xml:lang="ru"><trans-title>Вопросы гематологии/онкологии и иммунопатологии в педиатрии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-1708</issn><issn publication-format="electronic">2414-9314</issn><publisher><publisher-name xml:lang="en">Fund Doctors, Innovations, Science for Children</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">410</article-id><article-id pub-id-type="doi">10.24287/j.410</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>LITERATURE REVIEW</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОБЗОР ЛИТЕРАТУРЫ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="ru">Гранулематозное поражение кожи как проявление первичного иммунодефицитного состояния у детей.</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1907-4168</contrib-id><name><surname>Selezneva</surname><given-names>Olga Сергеевна</given-names></name><address><country country="RU">Russian Federation</country></address><bio><p>Врач аллерголог-иммунолог, отделения гематологии и онкологии с х/т, в детской областной клинической больнице г.Ростова на Дону. Являюсь также главным внештатным специалистом по детской аллергологии и иммунологии МЗ РО.</p></bio><email>seleznevaolga79@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1"><institution>ГБУ РО "Областная детская клиническая больница" Ростов-на-дону</institution></aff><pub-date date-type="pub" iso-8601-date="2021-01-11" publication-format="electronic"><day>11</day><month>01</month><year>2021</year></pub-date><volume>19</volume><issue>4</issue><issue-title xml:lang="en">supplement</issue-title><issue-title xml:lang="ru">приложение</issue-title><history><date date-type="received" iso-8601-date="2020-12-08"><day>08</day><month>12</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-12-25"><day>25</day><month>12</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2020, «D. Rogachev NMRCPHOI»</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2020, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="en">«D. Rogachev NMRCPHOI»</copyright-holder><copyright-holder xml:lang="ru">ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://hemoncim.com/jour/article/view/410">https://hemoncim.com/jour/article/view/410</self-uri><abstract xml:lang="ru"><p>Первичные иммунодефицитные состояния (ПИДС) представляют собой генетически гетерогенную группу заболеваний из более 400 нозологий. Традиционно ПИДС проявляются повышенной восприимчивоcтью к различного рода инфекционным заболеваниям. Тем не менее в последние десятилетие все большее значение приобретают неинфекционные осложнения связанные с дисрегуляцией и аутоиммунными расстройствами. У пациентов с ПИДС часто встречаются кожные проявления, и являются одним из признаков, позволяющих заподозрить диагноз иммунодефицита в раннем детстве. При этом одним из наименее изученных кожных проявлений ПИДС являются гранулематозный дерматит. Данный обзор посвящен обобщению данных исследований патогенеза, методов диагностики и терапии гранулематозного дерматита у пациентов с различными ПИДС</p></abstract><kwd-group xml:lang="ru"><kwd>гранулемы</kwd><kwd>дети</kwd><kwd>макрофаги</kwd><kwd>врожденный иммунитет</kwd><kwd>первичный иммунодефицит.</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Анна Щербина, ФГБУ "НМИЦ ДГОИ им. Д. Рогачева"</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Иммунология детского возраста. Практическое руководство по детским болезням. Под ред. А.Ю. Щербины и Е.Д. Пашанова. М.: Медпрактика-М, 2006. [Childhood Immunology. A practical guide to children’s illnesses. Ed.: A.Yu. Shcherbina, Ye.D. Pashanov. M.: Medpraktika-M, 2006. (In Russ.)]</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Picard C, Bobby Gaspar H, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, et al. International Union of Immunological Societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity. J Clin Immunol. 2018;38(1):96–128.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Bousfiha A, Jeddane L, Picard C, et al. Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification. J Clin Immunol. 2020;40(1):66–81.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Tangye SG, Al-Herz W, Bousfiha A, et al. Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee [published correction appears in J Clin Immunol. 2020 Feb 22;. J Clin Immunol. 2020;40(1):24–64.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Bousfiha A, Jeddane L, Picard C, et al. The 2017 IUIS Phenotypic Classification for Primary Immunodeficiencies. J Clin Immunol. 2018;38(1):129–143. doi:10.1007/s10875-017-0465-8</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Sharma D, Jindal AK, Rawat A, Singh S. Approach to a Child with Primary Immunodeficiency Made Simple. Indian Dermatol Online J. 2017;8(6):391–405.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Kuzmenko N.B., Shcherbina A.Y. Classification of primary immunodeficiencies as a reflection of modern ideas about their pathogenesis and therapeutic approaches. Russian Journal of Pediatric Hematology and Oncology. 2017;4(3):51-57. (In Russ.)</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Продуктивное воспаление: руководство для врачей. Повзун С.А. - Санкт-Петербург: спецЛит,2018, 359с. ISBN978-5-299-00937-8,</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Elbaz T, Esmat G. Hepatic and intestinal schistosomiasis: review. J Adv Res. (2013) 4:445–52.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Wilson MS, Mentink-Kane MM, Pesce JT, Ramalingam TR, Thompson R, Wynn TA. Immunopathology of schistosomiasis. Immunol Cell Biol. (2007) 85:148–54.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Martín-Callizo C, Marcoval J, Penín RM. Granulomatous Reactions to Red Tattoo Pigments: A Description of 5 Cases. Actas Dermosifiliogr. 2015;106(7):588-590.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Molina-Ruiz AM, Requena L (2015) Foreign body granulomas. Dermatol Clin 33(3):497–523.)</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Piette EW, Rosenbach M (2016) Granuloma annulare: pathogenesis, disease associations and triggers, and therapeutic options. J Am Acad Dermatol 75(3):467–479.)</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Mangold AR, Cumsky HJL, Costello CM, et al. Clinical and histopathologic features of paraneoplastic granuloma annulare in association with solid organ malignancies: A case-control study. J Am Acad Dermatol. 2018;79(5):913-920.e1.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Wanat KA, Elenitsas R, Kim EJ, Rosenbach M. Granuloma annulare associated with cutaneous marginal zone lymphoma: a case linking a hematologic malignancy with granulomatous dermatitis. Am J Dermatopathol. 2012;34(8):844-846.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet P-Y, Müller-Quernheim J. Sarcoidosis. Lancet. (2014) 383:1155–67.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Caso F, Galozzi P, Costa L, Sfriso P, Cantarini L, Punzi L. Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's disease. RMD Open. 2015;1(1):e000097. Published 2015 Jul 20.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Lo Schiavo A, Ruocco E, Gambardella A, O’Leary RE, Gee S (2014) Granulomatous dysimmune reactions (sarcoidosis, granuloma annulare, and others) on differently injured skin areas. Clin Dermatol 32(5):646–653.)</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Chua-Aguilera CJ, Möller B, Yawalkar N (2017) Skin manifestations of rheumatoid arthritis, juvenile idiopathic arthritis, and spondyloarthritides. Clin Rev Allergy Immunol 53(3):371–393.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Fischer A, Provot J, Jais JP, Alcais A, Mahlaoui N; members of the CEREDIH French PID study group. Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies. J Allergy Clin Immunol. 2017;140(5):1388-1393.e8.)</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Schuetz C, Huck K, Gudowius S, Megahed M, Feyen O, Hubner B, et al. An immunodeficiency disease with RAG mutations and granulomas. N Engl J Med. 2008;358:2030–2038 (ESID Registry - Working Definitions for Clinical Diagnosis of PID. (2014).A vailable online at:</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>ESID Registry – Working Definitions for Clinical Diagnosis of PID https://esid.org/content/download/13053/372959/file/ESIDRegistry_ClinicalCriteria2014.pdf (accessed December 15, 2019)</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Asai J (2017) What is new in the histogenesis of granulomatous skin diseases? J Dermatol 44(3):297–303.)</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Terziroli Beretta-Piccoli, B., Mainetti, C., Peeters, M. et al. Cutaneous Granulomatosis: a Comprehensive Review. Clinic Rev Allerg Immunol 54, 131–146 (2018).</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Wilson JL, Mayr HK and Weichhart T (2019) Metabolic Programming of Macrophages: Implications in the Pathogenesis of Granulomatous Disease. Front. Immunol. 10:2265.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Girgis NM, Gundra UM, Ward LN, Cabrera M, Frevert U, Loke P. Ly6C(high) monocytes become alternatively activated macrophages in schistosome granulomas with help from CD4+ cells. PLoS Pathog. (2014) 10:e1004080.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Silva DAAD, Silva MVD, Barros CCO, et al. TNF-α blockade impairs in vitro tuberculous granuloma formation and down modulate Th1, Th17 and Treg cytokines. PLoS One. 2018;13(3):e0194430. Published 2018 Mar 15.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Boros DL (2013) New perspectives on ancient granulomas. Front Immunol 4:345. https://doi.org/10.3389/fimmu.2013.00345</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Li X, Körner H, Liu X. Susceptibility to Intracellular Infections: Contributions of TNF to Immune Defense. Front Microbiol. 2020;11:1643. Published 2020 Jul 15.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Timmermans WM, van Laar JA, van Hagen PM, van Zelm MC. Immunopathogenesis of granulomas in chronic autoinflammatory diseases. Clin Transl Immunology. 2016;5(12):e118. Published 2016 Dec 16.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Huang Z, Luo Q, Guo Y et al . Mycobacterium tuberculosis ‐induced polarization of human macrophage orchestrates the formation and development of tuberculous granulomas in vitro. PLoS ONE 2015; 10: e0129744.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Essandoh K, Li Y, Huo J, Fan GC. MiRNA-Mediated Macrophage Polarization and its Potential Role in the Regulation of Inflammatory Response. Shock. 2016;46(2):122-131.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Jetten N, Roumans N, Gijbels MJ, et al. Wound administration of M2-polarized macrophages does not improve murine cutaneous healing responses. PLoS One. 2014;9(7):e102994. Published 2014 Jul 28.)</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Kumar R, Singh P, Kolloli A, et al. Immunometabolism of Phagocytes During Mycobacterium tuberculosis Infection. Front Mol Biosci. 2019;6:105. Published 2019 Oct 14.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Wojtan P, Mierzejewski M, Osinska I, Domagala-Kulawik J. Macrophage polarization in interstitial lung diseases. Cent Eur J Immunol 2016; 41: 159–164.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Mattila JT, Ojo OO, Kepka-Lenhart D, et al. Microenvironments in tuberculous granulomas are delineated by distinct populations of macrophage subsets and expression of nitric oxide synthase and arginase isoforms. J Immunol. 2013;191:773–784.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Khan A, Singh VK, Hunter RL, Jagannath C. Macrophage heterogeneity and plasticity in tuberculosis. J Leukoc Biol. 2019;106(2):275-282.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Terziroli Beretta-Piccoli, B., Mainetti, C., Peeters, M. et al. Cutaneous Granulomatosis: a Comprehensive Review. Clinic Rev Allerg Immunol 54, 131–146 (2018).</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Wick MR. Granulomatous &amp; histiocytic dermatitides. Semin Diagn Pathol. 2017;34(3):301-311.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Ito T, Connett JM, Kunkel SL, Matsukawa A (2013) The linkage of innate and adaptive immune response during granulomatous development. Front Immunol 4:10.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Norouzi S, Aghamohammadi A, Mamishi S, Rosenzweig SD, Rezaei N. Bacillus Calmette-Guérin (BCG) complications associated with primary immunodeficiency diseases. J Infect. 2012;64(6):543-554.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Clay H, Volkman HE, Ramakrishnan L. Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. Immunity 2008; 29: 283–294</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Ho HE, Cunningham-Rundles C. Non-infectious Complications of Common Variable Immunodeficiency: Updated Clinical Spectrum, Sequelae, and Insights to Pathogenesis. Front Immunol. 2020;11:149. Published 2020 Feb 7.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Kamphuis LS, van Zelm MC, Lam KH, Rimmelzwaan GF, Baarsma GS, Dik WA et al. Perigranuloma localization and abnormal maturation of B cells: emerging key players in sarcoidosis? Am J Respir Crit Care Med 2013; 187: 406–416.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Imadojemu S, Rosenbach M. Advances in Inflammatory Granulomatous Skin Diseases. Dermatol Clin. 2019;37(1):49–64.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Takeda, K. and Akira, S. 2015. Toll‐Like Receptors. Curr. Protoc. Immunol. 109: 14.12.1– 14.12.10. doi: 10.1002/0471142735.im1412s109</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Schmitt A, Volz A. Non-infectious granulomatous dermatoses. J Dtsch Dermatol Ges. 2019;17(5):518–533.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Holl-Ulrich K, Rose C. Nichtinfektiöse granulomatöse Entzündungen: Schwerpunkt Lunge und Haut [Non-infectious granulomatous inflammation: Focus on the lungs and skin]. Pathologe. 2016;37(2):172–182.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Moghaddas F, Masters SL. The classification, genetic diagnosis and modelling of monogenic autoinflammatory disorders. Clin Sci (Lond). 2018;132(17):1901-1924. Published 2018 Sep 5. doi:10.1042/CS20171498</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>de Jesus AA, Goldbach-Mansky R. Genetically defined autoinflammatory diseases. Oral Dis. 2016;22(7):591–604.</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999;97(1):133–144.</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Gandhi C, Healy C, Wanderer AA, Hoffman HM. Familial atypical cold urticaria: description of a new hereditary disease. J Allergy Clin Immunol. 2009;124:1245–1250.</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Hernández-Ostiz S, Xirotagaros G, Prieto-Torres L, Noguera-Morel L, Torrelo A. Enfermedades autoinflamatorias en dermatología pediátrica. Parte 2: síndromes histiocítico-macrofágicos y síndromes vasculopáticos. Actas Dermosifiliogr. 2017;108:620–629.</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Rose CD, Martin TM, Wouters CH. Blau syndrome revisited. Curr Opin Rheumatol. 2011;23(5):411–418.</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Figueras-Nart I, Mascaró JM Jr, Solanich X, Hernández-Rodríguez J. Dermatologic and Dermatopathologic Features of Monogenic Autoinflammatory Diseases. Front Immunol. 2019;10:2448. Published 2019 Oct 29.</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Ombrello MJ, Remmers EF, Sun G, et al. Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N Engl J Med. 2012;366(4):330–338.</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Zhou Q, Lee GS, Brady J, et al. A hypermorphic missense mutation in PLCG2, encoding phospholipase Cγ2, causes a dominantly inherited autoinflammatory disease with immunodeficiency. Am J Hum Genet. 2012;91(4):713–720.</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Novice T, Kariminia A, Del Bel KL, et al. A Germline Mutation in the C2 Domain of PLCγ2 Associated with Gain-of-Function Expands the Phenotype for PLCG2-Related Diseases. J Clin Immunol. 2020;40(2):267–276.</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Parackova, Z., Bloomfield, M., Vrabcova, P. et al. Mutual alteration of NOD2-associated Blau syndrome and IFNγR1 deficiency. J Clin Immunol 40, 165–178 (2020).</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Aderibigbe OM, Priel DL, Lee C-CR, Ombrello MJ, Prajapati VH, Liang MG, et al. Distinct cutaneous manifestations and cold-induced leukocyte activation associated with PLCG2 mutations. JAMA Dermatol. (2015) 151:627–34. 10.1001</mixed-citation></ref></ref-list></back></article>
